4DMedical (ASX:4DX) share price is lifting on its COVID-related technology

The healthcare company is moving to Phase 2 trials of its imaging technology that's helping COVID-19 patients.

| More on:
a smiling doctor looks at her computer screen with medical imaging X-rays on a light screen in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The  4DMedical Ltd (ASX: 4DX) share price is in the green this morning. That's after the healthcare company announced it will be conducting a clinical pilot with I-Med for its respiratory scanning technology.

At the time of writing, shares in the company are trading for $1.62 – up 1.57% after earlier hitting $1.65. The ASX All Ordinaries Index (ASX: XAO), meanwhile, is 0.75% lower.

Let's take a closer look at today's news.

4DMedical share price rises on latest announcement

In a statement to the ASX, 4DMedical announced an agreement to commence Phase Two of its clinical pilot program with I-MED Radiology Network (I-MED), after the successful completion of Phase One.

The company says its technology provided "valuable insights" into a plethora of respiratory diseases, including asthma, silicosis, and long-COVID. Long-COVID refers to the continuation of symptoms felt by some covid patients long after acquiring the infection.

Phase one trials were conducted in Victoria. 4DMedical says the next stage will be completed in a different state "over the remainder of the year". The company is still looking into a commercial partnership with I-MED going forward.

Investors clearly love today's announcement, judging by the rising 4DMedical share price.

Management commentary

4DMedical founder and CEO Andreas Fouras said:

We are very excited to be conducting a clinical pilot with I-MED – a leader of pioneering new medical imaging technologies – to provide doctors and patients with improved insight into their lung health. Phase One of the clinical pilot was an overwhelming success with radiologists and patients reporting strong positive feedback. Although the partnership is not generating revenue at this stage, we aim to secure a commercial XV LVAS contract with I-MED provided that Phase Two is successful.

I-MED General Manager of external partnerships and government relations Mark Simpson added

Patients involved in the Phase One pilot overwhelmingly reported a positive experience. Beyond the technical success of the program, this important comfort and compliance metric shows we can adopt such transformative technologies without detriment to patient satisfaction, sustaining our ongoing commitment to outstanding patient care.

4DMedical share price snapshot

Over the past12 months, the 4DMedical share price has increased around 14%. It's underperformed the All Ords Index by approximately 12 percentage points in that time.

4D Medical has a market capitalisation of around $342 million.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is up 15% on guidance upgrade?

Let's find out what is getting investors excited on Tuesday.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

3 reasons why the Sigma Healthcare share price could be a buy

This business has a very exciting outlook.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »